Potential drugs used in the antibody–drug conjugate (ADC) architecture for cancer therapy by Yaghoubi, S. et al.
J Cell Physiol. 2020;235:31–64. wileyonlinelibrary.com/journal/jcp © 2019 Wiley Periodicals, Inc. | 31
Received: 28 April 2019 | Accepted: 20 May 2019
DOI: 10.1002/jcp.28967
R EV I EW ART I C L E
Potential drugs used in the antibody–drug conjugate (ADC)
architecture for cancer therapy
Sajad Yaghoubi1 | Mohammad Hossein Karimi2 | Majid Lotfinia3,4 |
Tohid Gharibi5,6 | Motahare Mahi‐Birjand7 | Esmaeil Kavi8 | Fahimeh Hosseini9 |
Koushan Sineh Sepehr10 | Mehrdad Khatami11 | Nader Bagheri12 |
Meghdad Abdollahpour‐Alitappeh8
1Department of Clinical Microbiology, Iranshahr
University of Medical Sciences, Iranshahr, Iran
2Transplant Research Center, Shiraz
University of Medical Sciences, Shiraz, Iran
3Physiology Research Center, Kashan
University of Medical Sciences, Kashan, Iran
4Core Research Lab, Kashan University of
Medical Sciences, Kashan, Iran
5Immunology Research Center, Tabriz
University of Medical Sciences, Tabriz, Iran
6Department of Immunology, Faculty of
Medicine, Tabriz University of Medical
Sciences, Tabriz, Iran
7Infectious Disease Research Center, Birjand
University of Medical Sciences, Birjand, Iran
8Department of Nursing, School of Nursing,
Larestan University of Medical Sciences,
Larestan, Iran
9Department of Microbiology, School of
Medicine, Shahid Beheshti University of
Medical Sciences, Tehran, Iran
10Laboratory Sciences Research Center,
Golestan University of Medical Sciences,
Gorgan, Iran
11NanoBioelectrochemistry Research Center,
Bam University of Medical Sciences, Bam, Iran
12Cellular and Molecular Research Center, Basic
Health Sciences Institute, Shahrekord University
of Medical Sciences, Shahrekord, Iran
Correspondences Meghdad Abdollahpour‐
Alitappeh PhD, Department of Nursing, School
of Nursing, Larestan University of Medical
Sciences, Larestan, Iran.
Email: Abdollahpour1983@yahoo.com
Nader Bagheri PhD, Cellular and Molecular
Research Center, Basic Health Sciences




Cytotoxic small‐molecule drugs have a major influence on the fate of antibody–drug
conjugates (ADCs). An ideal cytotoxic agent should be highly potent, remain stable
while linked to ADCs, kill the targeted tumor cell upon internalization and release
from the ADCs, and maintain its activity in multidrug‐resistant tumor cells. Lessons
learned from successful and failed experiences in ADC development resulted in
remarkable progress in the discovery and development of novel highly potent small
molecules. A better understanding of such small‐molecule drugs is important for
development of effective ADCs. The present review discusses requirements making a
payload appropriate for antitumor ADCs and focuses on the main characteristics of
commonly‐used cytotoxic payloads that showed acceptable results in clinical trials. In
addition, the present study represents emerging trends and recent advances of
payloads used in ADCs currently under clinical trials.
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1 | INTRODUCTION
Paul Ehrlich, the famous German physician and scientist, was the first
to describe the term “chemotherapy” in the early 1900s for the use of
chemical agents to treat diseases. However, the modern application of
chemotherapy was introduced in the mid‐1900s by nitrogen mustard,
a cytotoxic chemical that targets rapidly dividing cancer cells (DeVita
and Chu, 2008; Goodman et al., 1946; Peters & Brown, 2015). Since
then, a great number of anticancer agents have been introduced for
the treatment of cancer patients, including methotrexate (MTX), 6‐
mercaptopurine (6‐MP), taxanes, vinca alkaloids, nitrogen mustard,
and anthracyclines (DeVita & Chu, 2008). These chemotherapeutic
agents not only have a small therapeutic index (maximum tolerated
dose/minimum efficacious dose [MTD/MED]), but also target both
normal and cancer cells. The off‐target toxicity, as well as the small
therapeutic index, leads to severe side effects in patients receiving
chemotherapy, representing a major drawback and limiting their
usage. To circumvent the limitations of the chemotherapeutic agents, a
large body of research has been devoted to find new drugs capable of
specifically fighting cancer and improving patient's life, leading to
evolution of targeted cancer therapies (E. G. Kim and K. M. Kim, 2015).
Monoclonal antibodies (mAbs), a distinct class of targeted
anticancer therapeutics, offer a number of advantages compared
with traditional chemotherapeutic agents, importantly including long
half‐life and great selectivity, which result in diminished off‐target
toxicity. The application of mAbs, as a promising strategy to treat
malignancies in clinical practice, dates back to 1997, when the first
mAb rituximab was successfully approved for the treatment of low‐
grade B‐cell lymphoma. These successes were followed by a number
of other mAbs approved by the United States Food and Drug
Administration (FDA) for the treatment of solid tumors and
hematological malignancies (Boyiadzis & Foon, 2008; Scott, Wolchok,
& Old, 2012). In spite of enormous successful experiences, there are
still drawbacks associated with the anticancer efficiency of unarmed
(or naked) mAbs, encouraging efforts to further increase the potency
of therapeutic mAbs (Sassoon & Blanc, 2013).
Covalently linking toxins or drugs to mAbs, as a targeted therapy,
promises the increased enrichment of toxin or drug molecules in
tumor cells by simultaneously sparing normal cells from the off‐target
effects, enhanced solubility of hydrophobic compounds, and the
elongation of plasma half‐life through prevention of renal clearance,
which in turn leads to an increased therapeutic window (Beck, Senter,
& Chari, 2011; Teicher & Chari, 2011). Over the years, investigators
have improved mAb effectiveness through several strategies in which
mAbs directly deliver the cytotoxic agents to cancer cells, including
antibody‐radionuclide conjugates (ARCs; the conjugation of radio-
nuclides to antibodies), recombinant immunotoxins (RITs; antibody‐ or
antibody fragment‐protein toxin fusion), antibody–enzyme conjugates
(conjugation of enzymes to antibodies), and antibody–drug conjugates
(ADCs; conjugation of small‐molecule drugs to antibodies), among
which only ARCs and ADCs have achieved clinical and regulatory
successes (Choudhary, Mathew, & Verma, 2011; Kreitman & Pastan,
2011; Steiner & Neri, 2011; Teicher & Chari, 2011; Winston, Fuller,
Evelegh, & Hurrell, 2001). The three former conjugates are beyond the
scope of this review and have been extensively covered elsewhere.
The present review first provides a brief introduction to ADCs and a
summary of their historical development against cancer. Then, we
mainly discuss the cytotoxic payloads used in ADC architecture and
the requirements making a payload compound suitable for develop-
ment of an ADC, particularly by focusing on their structural and
mechanistic features. Lastly, the present review highlights the
emerging trend of using payloads for ADCs and recent advances in
promising ongoing clinical studies.
2 | ANTIBODY–DRUG CONJUGATES
(ADCS)
ADCs represent a new class of protein‐based therapeutic agents which
combine the targeting capabilities, high selectivity, and stability of
mAbs with the cancer‐killing potential of highly potent payloads
(300–1,000Da, with sub‐nanomolar [nM] IC50 values) to increase
precise drug delivery in cancer cells (Beck, Wurch, Bailly, & Corvaia,
2010b; Behrens et al., 2015; Doronina et al., 2003; Dubowchik &
Walker, 1999; Jackson et al., 2014a; Sievers & Senter, 2013; Wagner‐
Rousset et al., 2014). In an ADC, the mAb is covalently conjugated to a
variable number of small‐molecule payloads through a linker, serving
as a targeted delivery agent to an antigen‐positive tumor cell detected
by the mAbs that allows for discrimination between healthy and
cancerous cells (Anderl, Faulstich, Hechler, & Kulke, 2013; DiJoseph
et al., 2004; Mullard, 2013; Peters & Brown, 2015). Figure 1 indicates
an ADC consisting of a mAb, a potent payload, and a linker. Such
immunoconjugates, as compared with traditional cytotoxic drugs, lead
to decreased toxicity and increased efficacy of the payloads, leading to
the decreased MED and increased MTD (Beck, Goetsch, Dumontet, &
Corvaia, 2017). ADCs generally mediate cancer cell death through the
following steps: (a) reorganization and binding to tumor antigens
F IGURE 1 Schematic structure of an antibody–drug conjugate
(ADC). A typical ADC comprises a monoclonal antibody conjugated
with a potent payload by a linker. Such a molecule can serve as a
potent anticancer agent able to selectively target and kill cancer cells
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through the mAb moiety, (b) the internalization of ADC–antigen
complex, and (c) the release of cytotoxic payload following ADC
degradation in the lysosome, allowing the payload to kill the
target cell. In this way, the payloads are delivered specifically into
the target cells through the mAb moiety with minimized unwanted
off‐target toxicity (Abdollahpour‐Alitappeh et al., 2019; Diamantis &
Banerji, 2016). Ideally, following their administration in blood, the
ADCs, as a prodrug, are nontoxic but, when binding to the target cell
and internalized into the target cell, the active drug is then released
from the ADCs and eradicates the cancer cells.
3 | THE HISTORY OF ADC PAYLOADS
The use of mAbs, as a vehicle, is not a new concept; conjugated mAbs,
antibodies armed with cytotoxic molecules, were first described in
the 1970s in preclinical models, but failed to translate into clinical
benefits. The clinical trials with murine IgG‐based ADCs, albeit with
limited success, were first reported in the 1980s. Early ADCs, known
as first‐generation ADCs, used classical chemotherapy drugs,
including N‐acetyl melphalan, idarubicin, mitomycin C, anthracycline,
vinca alkaloids, methotrexate, and doxorubicin linked to murine
mAbs (Diamantis & Banerji, 2016; Dosio, Brusa, & Cattel, 2011; Endo
et al., 1987; Kato, Tsukada, Hara, & Hirai, 1983; Pimm, Paul,
Ogumuyiwa, & Baldwin, 1988; Rowland, Pietersz, & McKenzie,
1993; Shefet‐Carasso & Benhar, 2015; Smyth, Pietersz, & McKenzie,
1987; Spearman, Goodwin, Apelgren, & Bumol, 1987). BR96‐
doxorubicin and KS1/4‐methotrexate were developed in the first‐
generation ADCs, consisting of doxorubicin and methotrexate as
payloads for the treatment of metastatic breast cancer and non‐
small–cell lung cancer, respectively (Elias et al., 1990; Trail et al.,
1993). Despite the successful development of ADCs, these early
conjugates showed limited efficacy, moderate potency, and low
activity in clinical trials, when compared with the parent drug, mainly
due to lack of drug potency (Chari, 1998). This is because of the fact
that drugs used in the first‐generation ADCs were not highly potent
and their concentrations in the serum were not in the optimal range.
In general, the real number of ADCs that are internalized is
frequently lower than ones binding to the surface of the target cells
(Bakhtiar, 2016; Chari, 2008), showing a need for more drug
molecules per cell or more potent drug molecules. It soon turned
out that a highly potent payload is essentially required for
development of a successful ADC.
Multiple promising efforts have been conducted to improve
therapeutic benefits and decrease adverse side effects of the
anticancer drugs (Panowski, Bhakta, Raab, Polakis, & Junutula,
2014; Peters & Brown, 2015). The lack of successful clinical results
in first‐generation ADCs, although initially discouraging, led to
discovery of more potent small‐molecule drugs. In the past 10 years,
innovations have led to the discovery of novel payloads able to
overcome the limitations encountered by first‐generation ADCs. The
payload potency was improved by using new drugs, including
microtubule‐targeting agents (maytansinoids and auristatins) or
DNA‐targeting agents (calicheamicins) that showed 100–1,000‐fold
more potency as compared with previously‐used payloads (Teicher &
Chari, 2011). The introduction of such novel drugs, accompanied
by improvement of mAbs and linker technologies, not only improved
all aspects of ADCs, but also resulted in new interest in the
ADC field, followed by introduction of second‐ and third‐generation
ADCs (Abdollahpour‐Alitappeh et al., 2019; Chari, 1998; Teicher &
Chari, 2011).
By using a highly potent drug calicheamicin, Wyeth and Celltech
could develop an anti‐CD33 ADC, gemtuzumab ozogamicin
(Mylotarg) (Sievers & Linenberger, 2001). However, gemtuzumab
ozogamicin, although approved in 2000 by the FDA, was later
withdrawn from the market in a required post approval study due to
growing concerns about clinical benefits and safety (Panowski et al.,
2014; Ravandi, 2011). In fact, gemtuzumab ozogamicin, in combina-
tion with chemotherapy, not only failed to show improved survival
but, quite the contrary, exhibited increased levels of fatal toxicity
when compared with chemotherapy alone (Beck et al., 2010a).
Nowadays, a variety of potent payloads can be used for development
of highly efficient ADCs, paving the way for the selection of rational,
modern, and next generation payloads in the ADC architecture.
4 | CYTOTOXIC PAYLOAD
CHARACTERISTICS
The cytotoxic drug, also known as “cytotoxic small molecule,
warhead, or payload,” is an important factor which influences the
properties and activities of ADCs. Although there are a great
number of known cellular toxins, only a few number of toxic
structures and, even lower, modes of actions have been identified to
be suitable for the ADC concept (Anderl et al., 2013). Of note, this is
because of the fact that the toxin, as an ADC payload, must fulfill a
number of requirements, including a potent cell toxicity, defined
mechanism of action, appropriate modified site where the original
drug is released from the conjugate into the tumor cell, the
maintenance of potency after conjugation, as well as acceptable
stability and solubility in aqueous formulation and physiological
conditions. What's more, the drug should be obtainable and
synthetically accessible under conditions of good manufacturing
practice (GMP) by a safe, efficient, and cost‐effective process (Beck
et al., 2017; Lu, Jiang, Lu, & Zhang, 2016; Schrama, Reisfeld, &
Becker, 2006; Teicher & Chari, 2011). Here, we focus on some of
the key features involved in payload requirements.
4.1 | Drug structure
In spite of limited possibilities in their structures, the payloads have
to allow the conjugation through a linker. In this light, payloads used
in ADC architectures must contain a functional group in their
structure suitable for the coupling to the antibody. The nature and
site of the modification have to be carefully selected to preserve the
potency of the parental drug. What's more, the payloads must
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maintain their potency when modified for conjugation or bound to
amino acids after mAb degradation in noncleavable ADCs.
Payloads must contain appropriate water solubility in aqueous
buffers, to facilitate conjugation to the antibody and ensure sufficient
solubility of the conjugate under physiological conditions. At the
same time, the payload must contain a sufficient stability in plasma
taking into account the long half‐life of the antibody moiety in
circulation. Importantly, the molecular size of the payload should be
small to reduce the immunogenicity risk (Anderl et al., 2013; Chari,
Miller, & Widdison, 2014). Last but not least, a great number
of cytotoxic small‐molecule drugs used in ADC structure are
hydrophobic; their hydrophobic nature leads to induced antibody
aggregation. The circumvent of this issue not only limits fast
clearance rates and immunogenicity, but also guarantees a long shelf
life of ADCs (Diamantis & Banerji, 2016).
4.2 | Drug potency
The inherent cytotoxic potency of a payload must be extremely high,
because of a low penetration of mAbs in tumors, limited expression
of antigens, ineffective internalization, and linker metabolization;
these may lead to a very limited number of payloads in the target cell
(Dosio et al., 2011). Studies using radiolabeled antibodies in cancer
patients demonstrated that as little as 0.003–0.08% of an injected
antibody dose may accumulate per gram of tumor (Bosslet et al.,
1998; Poli et al., 2013), highlighting the need for payloads capable of
cell killing at extremely low concentrations. Such potent payloads,
which affect critical cellular targets present in low copy numbers, will
only guarantee high cytotoxic activities against a genetically‐
heterogeneous environment of a tumor tissue as well as the
prevention of cancer cell escape through resistance mechanisms.
Based on above evidence, drug developers focus progressively on the
application of potent small‐molecule drugs able to kill cells at sub‐nM
concentrations. In addition, the importance of using very potent
drugs stems from economic considerations; antibodies are large
molecules (150 kDa), much larger than drugs, and it is not economical
to administer several grams of ADCs per patient.
4.3 | Intracellular drug targets
The target of the ADC payload should be placed inside the cell, as a
vast majority of newly‐introduced ADCs rely upon internalization of
the drug conjugates, beginning with the endocytosis of the
ADC–antigen complex, degradation of antibody or linker moieties
in the lysosome, and, eventually, release of the payload into the
cytoplasm of the target cell (Abdollahpour‐Alitappeh et al., 2019).
The targets of a majority of highly toxic agents from plants, animals,
and microorganisms are located outside the cells, for example, on
neuronal cells through blockage of ion channels or on disturbances of
blood clotting, therefore being unsuitable to be used as ADC
payloads. Based on above, the majority of ADCs described in
literature rely mainly on a small number of payloads able to target
one of the three cellular structures, including DNA, tubulin filaments,
or RNA. However, not all of the toxins belonging to these three
classes proved successful, as discussed below.
5 | CYTOTOXIC PAYLOADS USED IN ADC
ARTITECTURES
Among a wide variety of toxins known in nature, considering the
technical requirements mentioned above, there are only few toxic
agents suitable for ADC applications. Despite their different
intracellular targets, a great number of drugs, as well as, most
probably, their cognate ADCs, show a similar scenario: cell‐cycle
arrest (either in S or G2/M, depending upon the drug) and
subsequent apoptosis (Abdollahpour‐Alitappeh et al., 2019; Kovtun
& Goldmacher, 2007; Naito et al., 2000). These documents propose
that nondividing cells, which rest in the G0 phase, are most likely less
sensitive as compared with dividing cells, including cancer cells, to
these drugs as well as their cognate ADCs. In fact, nondividing cells
were demonstrated to have resistance to tubulin‐, microtubule‐, or
DNA‐targeting drugs (Drewinko, Patchen, Yang, & Barlogie, 1981;
Jedema et al., 2004; Rao, Freireich, Smith, & Loo, 1979), representing
that ADCs containing such drugs would also preferentially kill
dividing cancer cells (Kovtun & Goldmacher, 2007).
The payloads used in approved ADCs or currently being used in
ADC research and development are far more potent than previously‐
used ones and can generally fall into two distinct categories,
corresponding to distinct intracellular targets: microtubule‐targeting
agents and DNA‐damaging agents (Table 1; Diamantis & Banerji,
2016). In addition, there is a third group, called alternative payloads,
including an RNA polymerase II inhibitor α‐amanitin, which is under
investigation and development. Microtubule‐targeting agents, includ-
ing maytansinoids (LoRusso, Weiss, Guardino, Girish, & Sliwkowski,
2011) and auristatins (Senter & Sievers, 2012), and DNA‐disrupting
agents, including calicheamicin (Ricart, 2011), with potencies several‐
fold greater than conventional chemotherapeutic agents, exhibited
promising outcomes as ADC payloads in a variety of clinical studies.
5.1 | Microtubule‐targeting agents as ADC
payloads
Tubulin polymerization is essential for a variety of cellular processes,
including intracellular transport, mitosis, and structural integrity
maintenance. There are five known binding sites for microtubules,
including vinca alkaloid‐, colchicine‐, taxane‐, maytansine‐, and
laulimalide‐binding sites. Microtubule/tubulin targeting agents, ac-
cording to their mechanisms of action, can fall into two major
categories, including (a) tubulin polymerization promoters that
stabilize microtubule structures and (b) tubulin polymerization
inhibitors that destabilize microtubule structures (Chen, Lin, Arnst,
Miller, & Li, 2017). Microtubule‐targeting agents impede the capacity
of mitotic spindles for the segregation of chromosomes, lead to the
altered cytoskeletal architecture of cells, induce cell‐cycle arrest in
the G2/M phase, and cause cell death, making them a potential and
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striking target for drug discovery (Dumontet & Jordan, 2010). Vinca
alkaloids (including vinblastine and vincristine) and taxoids (including
paclitaxel and docetaxel) are examples of microtubule‐targeting
agents, acting by disrupting normal microtubule formation and
stabilizing altered microtubule structures, respectively, in a way that
interferes with normal microtubular degradation during mitosis
(Abal, Andreu, & Barasoain, 2003).
Blockage of tubulin polymerization has provided a fundamental
basis for development of ADCs recently entering clinical develop-
ment. Maytansinoids and auristatins, as highly potent microtubule‐
targeting agents, have been effectively used as payloads for a
number of clinically‐approved ADCs. Both payloads are powerful
inhibitors of microtubule assembly, which bind to tubulin in the
proximity of the vinblastine‐binding site (Bhattacharyya & Wolff,
1977; Gebleux & Casi, 2016), and lead to G2/M cell‐cycle arrest and
eventually apoptosis. This biocidal mechanism was demonstrated to
have high efficiency at killing rapidly‐proliferating cells (Gebleux &
Casi, 2016). Figure 2 indicates the mechanisms of action of
auristatins or maytansinoids on microtubule formation (Peters &
Brown, 2015; Steinmetz & Prota, 2018).
The widespread application of microtubule‐targeting agents is due
to their moderately selective toxicity for rapidly‐proliferating cells.
This not only gives an added measure of safety but also reflects the
importance of tubulin in the mitosis process. Nonetheless, a general
disadvantage of ADCs that use microtubule‐targeting agents as their
payload is that the payloads unfold their cytotoxic effect primarily on
proliferating cells because of their inherent mechanism of action. In
this way, some rapidly dividing noncancerous cells may be killed,
resulting in common side effects. In addition, quiescent and nondivid-
ing cells have more likely less sensitivity to the drug action and are
likely to escape the drug mechanism, possibly opening the way for
development of resistance. Importantly, this can be a disadvantage
because some of the tumor types, such as cancer stem cells (CSCs) or
tumor initiating cells (TICs), are inherently slow growing. However,
microtubule‐targeting agents are particularly cyotoxic to cancer cells
that divide and grow faster than most normal cells (Abdollahpour‐
TABLE 1 Two main categories of cytotoxic payloads used for antibody–drug conjugate (ADC) development: microtubule‐targeting agents
and DNA‐damaging agents
Main Payloads used in ADC Pipelines
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Alitappeh, Hashemi Karouei, Lotfinia, Amanzadeh, & Habibi‐Anbouhi,
2018; Chari, 1998; Chari et al., 2014; Hollander, Kunz, & Hamann,
2008; Lee et al., 1989). Of note, it is important to remember that most
mouse xenograft models contain tumors that grow much faster than
normal human tumors, therefore presumably providing a false
indication of efficacy for such agents that are extremely specific for
rapidly‐proliferating cells.
5.1.1 | Auristatins
A series of studies, started by Pettit et al. in the mid‐1960s to explore
potential effects of marine life forms as an anticancer drug source,
resulted in the discovery of dolastatin peptides from the shell‐less
mollusk Dolabella auricularia (sea hare): dolastatins 1–15, showing the
ability to strongly kill cancer cell lines (Anderl et al., 2013; Luesch,
Moore, Paul, Mooberry, & Corbett, 2001; Pettit et al., 1981, 1982,
1987, 1987, 1989a, 1989b, 1989c, 1990, 1993). In addition, the
parent compound was identified in cyanobacteria Symploca hydnoides
and Lyngbya majuscula, which are nourishment to the sea hare (Dan
et al., 2018). In further studies, dolastatins 10 and 15 were found to
have high cytotoxic activities against human cancer cell lines at
extremely low concentrations (with an average IC50 value in the sub‐
nM range), exhibiting the most promising peptides within the
dolastatin family capable of binding powerfully to tubulin, inhibiting
polymerization, and causing cell death (Anderl et al., 2013; Bai,
Friedman, Pettit, & Hamel, 1992; Bai, Pettit, & Hamel, 1990a; Bai, R.
Pettit, & Hamel, 1990b; Bai et al., 1993; Doronina et al., 2006;
Doronina et al., 2003; Quentmeier, Brauer, Pettit, & Drexler, 1992;
Steube et al., 1992). Lastly, in the 1990s, dolastatin 10 successfully
passed several Phase I clinical trials, and entered Phase II trials (Pitot
et al., 1999); however, dolastatin 10 was later withdrawn from
clinical studies because of disappointing results, including insufficient
activity, high systemic toxicity, and severe side effects, dampening
the hope of any therapeutic benefits (Banerjee, Wang, Mohammad,
Sarkar, & Mohammad, 2008; Doronina et al., 2003, 2006). Efforts to
address this issue and to establish the drug class in large quantities,
along with encouraging observations in the positive therapeutic
index and high potency found in preclinical models, resulted in
development of the potent water‐soluble synthetic dolastatin
analogs: termed as auristatins (Anderl et al., 2013).
Auristatins are potent microtubule‐targeting agents capable of
blocking tubulin assembly and leading to G2/M phase cell‐cycle
arrest, which result in the dividing cells to undergo apoptosis. They
impede the microtubule formation through binding to the β‐subunit
of α‐β tubulin dimers in the cytoplasm. The drug then acts by
inhibiting the GTP hydrolysis on the β‐subunit, leading to excessive
and continuous growth of microtubules (Figure 2; Bouchard, Viskov,
& Garcia‐Echeverria, 2014; Diamantis & Banerji, 2016; Sapra & Shor,
2013). As the microtubules lose their capacity to shorten and
separate sister chromatids during anaphase, the cell is frozen in the
metaphase stage of mitosis (Francisco et al., 2003). Auristatin PE
(also known as soblidotin or TZT‐1027) was the first described
synthetic dolastatin 10 analog that structurally differs in the absence
of the thiazole ring from the original dolaphenine residue, leading to
a terminal benzylamine moiety (Kobayashi et al., 1997). Auristatin PE
successfully entered Phase I and II clinical trials but eventually failed
to demonstrate significant anticancer benefits or any confirmed
response in patients suffering from cancer (Anderl et al., 2013; Patel
et al., 2006; Riely et al., 2007).
As a more effort to enhance in vivo efficiency, Seattle Genetics
has developed two novel auristatin derivatives, including mono-
methyl auristatin E (MMAE) and monomethyl auristatin F (MMAF),
F IGURE 2 Effects of auristatins and
maytansines on microtubule formation.
Auristatins interfere with the formation
of microtubules through binding to the
β‐subunit of α‐β tubulin dimers, causing
continuous and excessive growth of
microtubules. Maytansines block the
polymerization of tubulin dimmers,
preventing the formation of mature
microtubules
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fully synthetic drugs prepared from SAR (structure–activity relation-
ship) studies, showing no degradation in plasma and human liver
lysosomal environment, as well as in the presence of proteases
(Carter and Senter, 2008; Chen et al., 2017; Doronina et al., 2006;
Senter & Sievers, 2012). Despite the lack of adverse effects seen in
previous clinical trials with auristatins as well as increased
therapeutic index, MMAF and MMAE were found to be too toxic
to be used in their native form and then derivatized for use as
payloads in ADC development (Anderl et al., 2013; Carter & Senter,
2008; Doronina et al., 2006; Senter & Sievers, 2012). MMAE and
MMAF, which are currently being used as payloads in a large number
of ADCs by conjugating to the mAb cysteine residues, have been
chosen among a wide variety of candidates due to their great
potency, water solubility, physiological stability, and suitability for
the attachment of stable linkers (Beck et al., 2017; Maderna et al.,
2014; Rouleau et al., 2015). The fully synthetic nature of MMAE and
MMAF may give them a significant advantage as compared with
other payloads used for ADCs. Of note, the peptide‐like structure of
MMAE and MMAF can limit the conjugation effect on the physical
properties of the mAb (Anderl et al., 2013; Carter & Senter, 2008;
Doronina et al., 2006, 2003).
The main difference between MMAE and MMAF is the presence
of a phenylalanine residue at the C‐terminus of MMAF which
contributes to membrane impermeability. Because of its hydrophobic
nature, MMAE can diffuse out of the target cell and mediate
bystander effects, the killing of nearby cells. This feature, although
leading to MMAE to be more potent than MMAF as shown by in vitro
studies, seems to be a potential disadvantage for the application of
MMAE in ADCs targeting nonsolid hematological malignancies
containing homogenous antigen expression (Chen et al., 2017;
Okeley et al., 2010; Peters & Brown, 2015). Auristatins, specifically
MMAE and MMAF, constitute most of the commonly used payloads
in ADC architecture currently investigated, accounting for a majority
of cytotoxic payloads in ADC clinical trials. Other auristatin analogs
are also being studied by a variety of companies, such as Ambrx,
Novartis, Bayer, Pierre Fabre, Pfizer, and Sanofi/Genzyme (Beck
et al., 2017; Maderna et al., 2014; Rouleau et al., 2015).
5.1.2 | Maytansinoids
Maytansinoids, a family of cytotoxins with a macrolide structure, are
derivatives of natural cytotoxic agents known as maytansines
originally isolated in 1972 from the bark of an Ethiopian shrub
Maytenus serrata by Kupchan et al. (1972). In the following years, a
number of maytansine derivatives were isolated from bacteria,
mosses, and higher plants (Anderl et al., 2013; Cassady, Chan, Floss,
& Leistner, 2004; Rinehart & Shield, 1976). Maytansine and
maytansinoids prevent microtubule assembly similar to auristatins,
but are mechanistically similar to vinca alkaloids (Hamel, 1992); they
strongly prevent microtubule polymerization and the formation of
mature microtubules through binding to β‐subunit of tubulin at or
near the vinblastine‐binding site, mediating mitotic arrest in the cells
(Bhattacharyya & Wolff, 1977; Mandelbaum‐Shavit, Wolpert‐
DeFilippes, & Johns, 1976; Remillard, Rebhun, Howie, & Kupchan,
1975). The hydrolysis of the GTP molecule on the β‐subunit leads to
further disassembly of existing microtubules, which again freezes the
cell in metaphase and prevents cell division (Figure 2; Oroudjev et al.,
2010). The antimitotic effect of maytansines at sub‐nM concentra-
tions with an ED50 (effective dose) between 0.1 and 0.01 ng/ml
(Cassady et al., 2004) has made them a promising candidate for
anticancer drugs (Anderl et al., 2013; Cassady et al., 2004).
Nevertheless, maytansines failed to demonstrate therapeutic bene-
fits in human clinical trials because of their potential systemic
toxicity, low therapeutic index, as well as no significant response and
induced severe side effects in patients with cancers, largely because
of the lack of tumor specificity (Chari et al., 1992; Issell & Crooke,
1978; Ravry, Omura, & Birch, 1985).
However, their extremely high potency, excellent and
acceptable stability, as well as suitable solubility in aqueous solutions
made maytansines an attractive candidate for the development of
ADCs (Anderl et al., 2013; Beck et al., 2017; Chari et al., 1992). First
attempts to establish antibody‐conjugated maytansine derivatives
have been undertaken in the 1980s and early 1990s. Since then, a
number of disulfide‐containing maytansinoids, containing a methyl-
dithiopropanoyl group instead of the native N‐acetyl group, have
been evaluated and entered clinical trials (Chari et al., 1992).
Maytansinoids and their derivatives showed approximately 1,000‐
fold more in vitro cytotoxicity as compared with conventional
clinically‐used anticancer drugs (Kupchan et al., 1977). In addition
to a general drawback of all ADCs based on microtubule‐targeting
agents as mentioned above, maytansinoid‐based ADCs suffer from
additional disadvantages, including the hydrophobic characters
of the drug and the linker to be used. The free drug is membrane
permeable and can elicit uncontrollable and severe side effects.
The hydrophobic nature of the linkers used for maytansinoid‐based
ADCs leads to increased conjugate aggregation or diminished binding
capacity of the antibody particularly at high drug loads, exhibiting a
high effect on the applicability of maytansine‐based ADCs
(Anderl et al., 2013; Chari, 1998; Hollander et al., 2008). More
importantly, drug transporters mainly facilitate the efflux of
hydrophobic compounds (Szakacs, Paterson, Ludwig, Booth‐Genthe,
& Gottesman, 2006; Takeshita et al., 2009). Therefore, maytansinoid‐
based ADCs are substrates for multidrug resistance protein 1
(MDR1; also called permeability glycoprotein 1, P‐glycoprotein 1
[P‐gp or Pgp], ATP‐binding cassette subfamily B member 1 [ABCB1],
or cluster of differentiation 243 [CD243]) that is a critical
protein of the cell membrane having the ability to pump a wide
variety of foreign substances out of cells. Therefore, several highly
water‐soluble hydrophilic linkers (including Sulfo‐SPDB and
Mal‐PEG4‐NHS) are under development to increase their solubility
and mediate the preparation of more hydrophilic ADCs. These
hydrophilic linkers result in production of ADCs with higher
drug loads, deliver of higher drug concentrations to the target cell,
and more polar maytansinoid metabolites inside the cell which are a
poor substrate for MDR efflux pumps and therefore overcome MDR
(Zhao et al., 2011).
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Maytansines, however, possessed no obvious functional group for
conjugation to an antibody molecule (Chari et al., 2014). The first
step to overcome the problem was to develop maytansine analogs
incorporating a thiol‐containing substituent, which were able to
undergo disulfide exchange with a suitably modified antibody to give
a conjugate. DM1 and DM4 are thiol‐bearing maytansinoids contain-
ing methyl disulfide substitutions at the C3 N‐acyl‐N‐methyl‐L‐alanyl
ester side chain of maytansine (Dan et al., 2018). DM1, which was
described first in 1992 and linked to antibodies via different linkers,
is an extremely potent maytansinoid developed by Immunogen,
showing a free drug IC50 of 0.1–1.0 nM. The ADC trastuzumab‐DM1
(T‐DM1), in which DM1 is coupled with trastuzumab through a
noncleavable linker, was the third FDA‐approved ADC for cancer
therapy in human beings. The drug is thought to bind to the antibody
outside the cell until the entire ADC is transported through
endocytosis into the cytoplasm (Lewis Phillips et al., 2008). After
intracellular processing of the ADC, a lysyl‐modified but still
cytotoxic form of DM1 is released, leading to antitubulin‐associated
cell death. The charged form of the drug shows no membrane
permeability and therefore no abovementioned bystander effect of
killing neighboring cells (Kovtun et al., 2006; Lewis Phillips et al.,
2008). A study carried out by Pillow showed that site‐specific
conjugation of maytansinoid payloads could improve the effective-
ness of the resultant ADCs (Pillow et al., 2014). In a study, Widdison
et al. (2015) indicated that an anilino‐linked maytansinoid leads to
improved bystander effects when compared with traditional dis-
ulfide‐linked maytansinoids. In collection, maytansinoid‐based ADCs
are an attractive approach which is believed to be greatly validated
following the FDA‐approval of ado‐trastuzumab emtansine (T‐DM1).
5.1.3 | Tubulysins
Tubulysins are a series of naturally occurring antimitotic tetrapep-
tides first isolated from myxobacteria by by Höfle et al. in 2000
(Sasse et al., 2000). When screening myxobacterial culture extracts
for biologically active compounds, Höfle et al. showed the isolation of
four members of the tubulysin family (A, B, D, and E) (Murray,
Peterson, & Fecik, 2015; Sasse et al., 2000). These natural products
are functionally similar to dolastatins, representing approximately
100‐ to 1,000‐fold more potent in comparison with traditional
chemotherapeutic agents with EC50 in the nM to sub‐nM range
(Chen et al., 2017).
Tubulysins, similar to auristatins and maytansines, are microtubule‐
disrupting agents, which inhibit microtubule polymerization, prevent cell
growth and division during mitosis, and induce cell death. Their known
biological activities can be summarized as follows: Tubulysins, upon
release, bind to the vinca domain of tubulin with higher affinity than
vinblastine, and rapidly decompose the cytoskeleton and mitotic
machinery of dividing cancer cells, resulting in tubulin depolymerization,
G2/M accumulation, and apoptosis (Kaur et al., 2006). The exceptional
antiproliferative activity of tubulysins has resulted in a great deal of
interest in evaluating their clinical potential and studying their
mechanism of action. In growth inhibition assays, tubulysins were found
to be inactive against bacteria and yeasts, and weakly active against
fungi. However, because of their remarkable ability to inhibit tubulin
polymerization, tubulysins have been exploited to target human cancer
cell lines, showing extremely potent antiproliferative activity against a
great number of human cancer cells including breast, cervix, colon,
leukemia, lung, melanoma, ovarian, and prostate cancer cells. Tubulysins
demonstrated not only to have a degree of selectivity against human
cancer cells because of their rapid division rates, but also to be effective
in MDR cancer cells that either overexpress P‐glycoprotein pumps or
have tubulin mutations. Therefore, they may bypass the obstacles
associated with the efflux pumps for DM1 (Balasubramanian, Raghavan,
Begaye, Sackett, & Fecik, 2009; Kaur et al., 2006; Khalil, Sasse, Lunsdorf,
Elnakady, & Reichenbach, 2006; Li et al., 2016; Murray et al., 2015;
Sasse et al., 2000; Steinmetz et al., 2004).
So far, approximately 14 different tubulysin isoforms have been
reported with a conserved core structure consisting of an L‐isoleucine
(Ile), a tubuvaline (Tuv), and an N‐methylD‐pipecolic acid (Mep) unit.
All natural tubulysins have a special N,O‐acetal and either a
tubutyrosine (Tut) or a tubuphenylalanine (Tup) at the C‐termini
for their biological function. What's more, it has been demonstrated
that N,O‐acetal can be replaced by a plain alkyl group to offer N‐14‐
desacetoxytubulysin H with no loss in potency.
Taken together regarding their high cytotoxic potency against a
wide variety of cancer cells, especially MDR cancer cells, tubulysins
have been a favored choice as payloads for the selective targeting of
cancer cells through ADCs. Based on the SAR study of the tubulysins,
this class allows many conjugation and targeting strategies, and is
well‐suited for any kind of conjugation to polymers or biomolecules
including mAbs. Taking advantage of the high folate receptor
expression in a number of cancers, tubulysin B–folic acid conjugate
(EC0305) was the first targeted drug involving tubulysin. Since then,
multiple ADCs carrying tubulysin as a payload have been exploited.
Tubulysin D, the most potent member of the tubulysin family with
IC50 values between 0.01 and 10 nM, has the ability to cause
multipolar spindles, which was initially conjugated with polymers to
offer proof‐of‐concept studies in preclinical models. Currently,
several ADCs bearing tubulysin D, as a payload, are under active
development, which deliver tubulysin selectively to cancer cells and,
therefore, avert toxic effects on normal tissues.
Importantly, computer‐assisted drug design and biological electronic
principles have mediated the synthesis of several tubulysin derivatives
with appropriate biological activity. However, the clinical pharmacolo-
gical data of these compounds have not yet been documented (Chen
et al., 2017; Cohen et al., 2014; Diamantis & Banerji, 2016). In collection,
tubulysins are projected to be an attractive new class of tubulin
inhibitors, whose analogs can be successfully conjugated to mAbs for
the development of a potent and stable ADC.
5.1.4 | Other microtubule‐targeting agents as ADC
payloads
In addition to the abovementioned microtubule‐targeting payloads,
there are other payloads targeting microtubules under investigation.
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Although they have not yet been successfully used as anticancer
agents, such compounds may have the great potential to be applied
as ADC payloads. However, there are little data to date supporting
their effectiveness and advantages.
Cryptophycins are a class of dioxadiazacyclohexadecenetetrone
cytotoxins with more potency than MMAE and DM1, first isolated in
the early 1990s from the cultures of Nostoc cyanobacteria. Cryptophy-
cins can bind to microtubules at the vinca‐binding site and induce
tubulin depolymerization, eventually leading to mitotic arrest. Crypto-
phycin‐1 is the most abundant component, demonstrating to be highly
potent against a wide range of solid tumors as well as MDR cancer
cells. Cryptophycin‐52 (also known as Cr‐52 and LY355703), a highly
potent synthetic version of cryptophycin, successfully passed Phase I
and reached Phase II clinical trials but was withdrawn because of side
effects. Cryptophycins show relative hydrophilicity, high potency, and
lack of P‐gp susceptibility, making them an attractive payload for ADC
architecture (Chen et al., 2017; Steinkuhler et al., 2016). Hemiasterlin
is a small family of naturally occurring tripeptides derived from marine
sponges, representing a potent inhibitor of cell growth. Hemiasterlin
binds to the vinca‐peptide site in tubulin, disrupts normal microtubule
dynamics, and inhibits tubulin polymerization. HTI‐286 (also known as
taltobulin), a fully synthetic analog of hemiasterlin, was demonstrated
to be active against various MDR cancer cells. Hemiasterlin‐based
ADCs demonstrated to have reduced toxicity, suitable therapeutic
window, and excellent cytotoxicity against a wide variety of tumor
cells (Chen et al., 2017; Loganzo et al., 2003). Cemadotin, also known
as LU103793, is a synthetic, pentapeptide, water‐soluble analog of
dolastatin 15, representing potent antiproliferative and antitumor
activities through inhibiting microtubule assembly and tubulin poly-
merization. Cemadotin exerts its antitumor activity by suppressing
spindle microtubule dynamics through binding at a new site in tubulin,
showing to be effective payloads for ADC synthesis (Bernardes et al.,
2012). Rhizoxin is a macrocyclic lactone compound isolated from the
pathogenic plant fungus Rhizopus microspores which is capable of
binding to tubulin and inhibiting microtubule assembly. Rhizoxin
showed the preclinical antitumor activity against several human tumor
cell lines and xenograft models (McLeod et al., 1996; Prota et al.,
2014). Discodermolide is the most potent natural promoter of tubulin
assembly, showing to be promising candidates for ADC synthesis.
Other tubulin inhibitors under investigation include taccalonolide A or
B, taccalonolide AF or AJ, epothilone A and B, taccalonolide
AI‐epoxide, colchicine, CA‐4, laulimalide, paclitaxel, and docetaxel, as
well as their synthetic derivatives (Chen et al., 2017).
5.2 | DNA‐damaging agents as ADC payloads
DNA‐damaging agents have a long history in cancer chemotherapy
for either reducing tumor growth or eliminating tumor cells.
DNA‐damaging agents are a set of cytotoxic payloads which exert
their cytotoxic effects through DNA binding in the double‐helix
minor groove, and lead to the scission, alkylation, intercalation, or
cross‐linking of the nucleic acid strands (Figure 3; Gebleux & Casi,
2016). Table 1 indicates some of the important DNA‐damaging
agents used in ADC architecture. Representative examples of this
class include camptothecin and anthracycline agents (DNA‐inter-
calators), calicheamicin and uncialamycin (DNA double‐strand
breakers), as well as pyrrolobenzodiazepine and duocarmycin
payloads (DNA alkylators), each of which may be tailored as a
mono‐alkylator or a bis‐alkylator (DNA‐cross linker). Drugs belong-
ing to this class are highly potent, with free drug IC50 < 1.0 nM, and
cause cell death (Lee et al., 1989; Thorson et al., 2000). Growing
evidence suggested that DNA‐damaging agents have suitable
activity in a number of MDR cancer cells and are more efficient in
killing tumor cells as compared with microtubule‐targeting agents,
specifically in solid tumors.
It is believed that DNA‐damaging agents have two potential
advantages over microtubule‐targeting agents, as ADC payloads: (a)
DNA‐damaging agents (picomolar [pM] IC50 values) show higher
potency as compared with microtubule‐targeting agents (sub‐nM
IC50 values), enabling ADCs to target tumor cells with low expressed
antigens, and (b) DNA‐damaging agents were shown to have
excellent activity throughout the various cell‐cycle phases, demon-
strating exquisite potency against dividing and nondividing cells,
particularly nondividing CSCs (Fu & Ho, 2018; Maugeri‐Sacca,
Bartucci, & De Maria, 2012).
5.2.1 | Pyrrolobenzodiazepines
Pyrrolobenzodiazepines (PBDs) are a series of natural products with
antibiotic or antitumor properties originally isolated from Streptomyces
F IGURE 3 Mechanism of actions of DNA‐damaging agents. DNA‐damaging agents can fall into roughly four mechanistic categories: DNA
double‐strand breakers, DNA alkylators, DNA intercalators, and DNA cross‐linkers. DNA‐damaging agents, compared with microtubule‐
targeting agents, can kill target cells at any point in their life cycle
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species in the 1960s. After discovery of anthramycin as the first PBD,
investigations led to identification of more than 12 naturally occurring
PBDs (Antonow & Thurston, 2011; Leimgruber, Stefanovic, Schenker,
Karr, & Berger, 1965). PBD molecules represent a significant class of
sequence‐specific DNA‐alkylating agents which covalently bind to the
C2‐amino groups of a guanine residue in the minor groove of double‐
stranded DNAs (Antonow & Thurston, 2011; Cipolla, Araujo, Airoldi, &
Bini, 2009; Gerratana, 2012; Hartley, 2011; Kamal, Reddy, Devaiah,
Shankaraiah, & Reddy, 2006; Mantaj, Jackson, Karu, Rahman, &
Thurston, 2016). PBDs are unable to bind to single‐stranded DNA (or
RNA), representing extremely selective in the requirement of a minor
groove structure for covalent binding to duplex or hairpin DNA
(Rahman, Corcoran, Bui, Jackson, & Thurston, 2014; Rahman et al.,
2009a). In addition, they were demonstrated to have a kinetic
preference for a three‐base‐pair recognition sequence, 59‐Py–G–Py‐
39 (in which Py = pyrimidine and G = reacting guanine) (Rahman,
Vassoler, James, & Thurston, 2010). PBDs, when bound, remain
unattached in the DNA minor groove forming the PBD/DNA adduct,
which lead to avoiding DNA repair via slight distortion of the helix and
inhibiting several biological processes, such as binding of transcription
factors to DNA and some enzyme functions including RNA polymerase
and endonucleases (Brucoli et al., 2013; Clingen et al., 2005; Hsieh
et al., 2011; Jackson, James, Jenkins, Rahman, & Thurston, 2014b;
Kopka et al., 1994; Kotecha et al., 2008; Puvvada et al., 1997; Puvvada,
Hartley, Jenkins, & Thurston, 1993; Rahman et al., 2013; Wells et al.,
2006). These block cell division with no distortion of the DNA helix,
therefore potentially causing lethal lesions. PBDs showed strong
antitumor or antibiotic activities as compared with chemotherapeutic
agents. Importantly, tumor cells frequently display deficiency in
one or more related DNA repair pathways, therefore resulting in
selective antitumor activities (Farmer et al., 2005; Mantaj et al., 2016).
Most importantly, PBD adducts were demonstrated to be preferen-
tially repaired in healthy cells in comparison with tumor cells
(Andreassen & Ren, 2009).
There are currently two subfamilies of PBDs, including naturally
occurring PBD monomers capable of forming singly‐alkylated DNA‐
adducts and synthetic PBD dimers consisting of two PBD units
coupled via a C8/C8′‐linker capable of forming intrastrand or
interstrand DNA cross‐links in addition to monoadducts (Gregson
et al., 2001; Mantaj et al., 2016; Rahman, James, & Thurston, 2011b;
Rahman, James, Bui, Drake, & Thurston, 2011a; Rahman, Thompson,
James, Narayanaswamy, & Thurston, 2009b). The PBD monomer
includes the agents first isolated from Streptomyces species (e.g.,
tomaymycin and anthramycin) and a number of recently‐introduced
synthetic analogs developed over the last 50 years (including
Limazepines A‐F) (Antonow & Thurston, 2011; Fotso et al., 2009;
Mantaj et al., 2016). The PBD monomers exhibit antibacterial and
antitumor properties (Kotecha et al., 2008). To investigate PBDs with
sequence‐binding selectivity, Thurston developed a PBD dimer
through linking two PBDs, resulting in production of PBD dimers
with 600‐fold activity in vitro (Mantaj, Jackson, Rahman, & Thurston,
2016). This makes PBD dimers a promising payload for use in ADC
architecture. PBD dimers bind specially to guanidine residues on
various positions in the double‐stranded DNA helix and drive DNA
strand cross‐linking. Of important note, dimerization improves the
PBD binding affinity, sequence specificity, and efficacy. PBD dimers
showed potent in vitro antitumor cytotoxicity (IC50 values with the
mid to low pM ranges) against a broad range of tumor cell lines. Most
importantly, PBD dimers indicate acceptable activity in MDR1 and
refractory tumors because of the fact that they are normally not
substrates of MDR1 (Mantaj, Jackson, Rahman, & Thurston, 2017),
significantly avoiding the commonly‐observed drug resistance. The
cytotoxicity of PBD dimers seems to stem from the inability of repair
proteins to appropriately recognize DNA damage, leading to slow‐
progressing repair rates of monoadducts, and cross‐links present in
the minor groove of DNA (Clingen et al., 2005). Although interstrand
crosslink, intrastrand cross‐links, and monoadducts can be formed by
PBD dimers (Rahman et al., 2009b), the interstrand cross‐linked
adduct is believed to be the main toxic form in cells.
Unlike microtubule‐targeting agents, PBD monomers and dimers
can lead to cell death in both dividing and nondividing cells. Due to
their high potency, great intracellular targets, completely different
cellular mechanism (as compared with tubulin inhibitors), different
mode of DNA interaction (as compared with other DNA‐damaging
agents such as calicheamicin), as well as a small tendency for the
development of drug‐resistant phenotypes, natural or synthetic
PBDs and PBD dimers can serve as appropriate payloads for the
synthesis of ADCs. PBD monomers and dimers are becoming
established as important next‐generation payloads in the ADC
therapeutic field. Of note, PBD dimers can even be more attractive
cytotoxic payloads for use in ADCs because of their higher potency
and interesting mechanism of action (Gregson et al., 2001).
5.2.2 | Duocarmycins
Duocarmycins, a family of naturally occurring antibiotic metabolites,
are extremely powerful antineoplastic compounds originally isolated
from Streptomyces bacteria in the late 1970s (Yasuzawa et al., 1988).
They consist of an indole moiety (serving as a DNA‐binding
component) and an unprecedented spirocyclopropylcyclohexadie-
none moiety (serving as a pharmacophore group), which lead to
selective alkylation of DNA sequences (Hurley et al., 1988).
Duocarmycins represent powerful cytotoxic DNA minor groove‐
alkylating agents which exert their high potency through the
formation of DNA adduct. Duocarmycins selectively prefer a five‐
base‐pair AT‐rich sequence that better accommodates the central
pyrroloindole subunit. In terms of mode of action, duocarmycins bind
to the DNA minor groove, N3 of adenine attacks the cyclopropane
moiety within the DNA minor groove thus forming a DNA adduct,
and alkylation of adenines occurs at the N3 position. The induced
irreversible DNA alkylation hinders DNA architecture and structural
integrity, and leads to DNA cleavage and, eventually, cell death
through apoptosis (Boger & Johnson, 1995). A recent controversial
theory claimed that duocarmycins could also act through the
inhibition of aldehyde dehydrogenase 1, an enzyme playing critical
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roles in cancer cell detoxification and viability (Tercel et al., 2013;
Wirth et al., 2013; Wirth, Schmuck, Tietze, & Sieber, 2012).
Adozelesin, bizelesin, and carzelesin, members of the cyclopro-
pylpyrroloindole family, are artificially synthesized analogs of
duocarmycins. These drugs have achieved high research and clinical
attention and have advanced into clinical studies for cancer
treatments. Adozelesin is an alkylating small groove DNA‐binding
agent which quickly restrains the replication of DNA in treated cells
via a trans‐acting mechanism, primarily arresting cells in the S phase.
Bizelesin targets the DNA small groove and causes DNA cross‐
linking, thereby restraining DNA replication and RNA synthesis. It
also strengthens the induction of p21 and p53 and induces G2/M
cell‐cycle arrest, leading to slow cell death but without any apoptosis.
Carzelesin is a cyclopropylpyrroloindole prodrug consisting of a
nonreactive chloromethyl forebody that is functional upon activation.
It is activated by hydrolysis of the phenylurethane substituent to
generate U‐76073 and a subsequent ring closure step yields the
cyclopropyl‐containing U‐76074 form that is active in DNA binding
(Dokter et al., 2014; Li et al., 1992; Sugiyama, Lian, Isomura, Saito, &
Wang, 1996; Tietze, Krewer, von Hof, Frauendorf, & Schuberth,
2009). CC‐1065 and duocarmycin SA are the most widely used
molecules among duocarmycin analogs (Dokter et al., 2014; Li et al.,
1992; Sugiyama et al., 1996; Tietze et al., 2009).
Duocarmycin and its analogs display impressively high cytotoxi-
city against the growing cancer cells in culture, showing strong
cytotoxic properties with IC50 values in the pM range against a
variety of cell lines (Tietze & Schmuck, 2011). Duocarmycins are
capable of applying their mode of action at any stages of cell‐cycle,
representing better antitumor activities as compared with micro-
tubule‐targeting agents that only attack tumor cells during the
mitotic state. What's more, duocarmycin analogs have also been
demonstrated to be effective on solid tumors and various MDR
models (Diamantis & Banerji, 2016; Dokter et al., 2014; Li et al.,
1992; Sugiyama et al., 1996; Tietze et al., 2009). However, despite
their high antitumor activity, duocarmycins can not directly used for
cancer chemotherapy, making them excellent candidates as payloads
for ADC synthesis.
A duocarmycin analog DUBA (duocarmycin–hydroxybenzami-
de–azaindole), the final active drug form, has been developed into
several new‐generation ADCs for in vitro or in vivo efficacy
evaluations. SYD983, an anti‐HER2 ADC, is a leading ADC derived
from this platform, showing decreased tumor growth in a BT‐474
mouse xenograft and acceptable stability in the plasma of human and
cynomolgus monkey (Dokter et al., 2014; Li et al., 1992; Sugiyama
et al., 1996; Tietze et al., 2009). In collection, the high potency of
duocarmycins and their analogs not only makes them an appropriate
candidate for maximizing ADC cell‐killing potency, but also may be
effective against MDR cancer cells.
5.2.3 | Doxorubicins
Doxorubicin, an actinomycete‐derived antimitotic anticancer agent
often regarded by the trade name Adriamycin, is a member of the
anthracycline compounds originally isolated in the 1970s from
Streptomyces peucetius (Arcamone et al., 1969; Di Marco, Gaetani, &
Scarpinato, 1969; Yang, Teves, Kemp, & Henikoff, 2014). Doxorubicin
is a 14‐hydroxylated version of daunorubicin which has been used
with great efficacy to treat a broad range of solid and nonsolid
tumors, representing as one of the most impactful antitumor
chemotherapeutic agents widely used in the clinic (Yang et al., 2014).
Although extensively used in the clinics, the molecular mechan-
ism(s) of doxorubicin driving cardiotoxicity or cell death remains to
be elusive. However, two seemingly conflicting models have been
proposed for doxorubicin‐mediated cell death through inducing DNA
damage, including (a) DNA helix intercalation and disruption of
topoisomerase II‐mediated DNA repair and (b) development of free
radicals and subsequent damage to cellular membranes, DNA and
proteins (Gewirtz, 1999). Briefly, the oxidization of doxorubicin first
leads to the formation of an unstable metabolite, semiquinone, which
is then converted back to doxorubicin in a process releasing reactive
oxygen species. The reactive oxygen species can in turn result in lipid
peroxidation, membrane and DNA damage, increased cellular
oxidative stress, and induction of cell death through apoptosis
(Doroshow, 1986; Thorn et al., 2011). Otherwise, doxorubicin can
enter the nucleus and poison topoisomerase II, causing DNA damage
and subsequent cell death (Tewey, Rowe, Yang, Halligan, & Liu,
1984). There is also evidence supporting that doxorubicin leads to
DNA adduct formation, free radical generation, and ceramide
overproduction (Gewirtz, 1999; Minotti, Menna, Salvatorelli, Cairo,
& Gianni, 2004; Senchenkov, Litvak, & Cabot, 2001). As a DNA
intercalator, doxorubicin forms hydrogen‐bonds with guanine and
intercalates into the DNA strand at sites with adjacent GC base pairs,
therefore inhibiting DNA replication and, eventually, protein synth-
esis. This process has been demonstrated to trigger DNA damage
responses and induce cell death (Bouchard et al., 2014; Brown,
Sandhu, & Herrmann, 2015; Yang et al., 2014). DNA intercalation and
induced topoisomerase II poisoning are thought to be major
doxorubicin mode of actions which result in DNA damage and cell
death. Nevertheless, the most well‐known mechanism of doxorubicin
seems to be through topoisomerase II poisoning, where it traps the
topoisomerase II at the DNA breakage sites, resulting in an increased
and stabilized cleavable enzyme‐DNA linked complex during DNA
replication and subsequent prevention of the nucleotide strand
ligation after double‐strand breaks. Simply stated, Topoisomerase II
poisoning by doxorubicin is thought to disrupt DNA replication and
transcription, leading to apoptosis‐mediated cell death. Additionally,
the oxidation of doxorubicin quinone structure leads to semiquinone
radical formation and subsequent superoxide and H2O2
generation, resulting in elevated oxidative stress and eventually
DNA damage. Along with increased cellular oxidative stress,
doxorubicin treatment also results in an increased cellular ceramide
level, triggering processes such as growth arrest, apoptosis, and
senescence. However, some of these functions, such as inhibition of
DNA and RNA synthesis, are only observed at doses higher than the
clinical dose (approximately 40–60mg/m2; Bouchard et al., 2014;
Brown et al., 2015; Gewirtz, 1999; Yang et al., 2014).
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Despite their clinical importance, the occurrence of drug
resistance and side effects lead to a narrow therapeutic window,
representing the main drawbacks for successful cancer treatment
(Thorn et al., 2011). For this regard, ADCs based on doxorubicin and
other doxorubicin derivatives have been designed and synthesized to
improve its unfavorable parameters and therapeutic window. An
ADC consisting of a chimeric anti‐LewisY cBR96 mAb coupled with
doxorubicin was shown to release the payload inside the cytosome of
targeted cancer cells, thereby, increasing the total efficacy of
doxorubicin (Bouchard et al., 2014; Brown et al., 2015; Yang et al.,
2014). BMS‐182248 was the first doxorubicin‐based ADC to reach
Phase II clinical trials in patients with non‐small‐cell lung cancer.
However, Seattle Genetics later made a decision to cease its
development, although the data were encouraging (Beck et al., 2017).
5.2.4 | Calicheamicins
Calicheamicins, also known as LL‐E33288 antibiotics, represent a
class of enediyne‐containing DNA‐cleaving antitumor agents origin-
ally discovered by the Lederle Laboratories (American Cyanamid Co.)
in the mid‐1980s when conducting a research for development of
novel fermentation‐derived antitumor antibiotics in Micromonospora
echinospora. In the meantime, scientists found that the bacterium
produced a compound in the culture media which is an incredibly
potent cytotoxic agent. This class of drugs was found to be related
structurally to other enediynes such as neocarzinostatin, esperami-
cins, kedarcidin, C‐1027, maduropeptin, dynemicins, shishijimicin,
and namenamicin. The compound was then found to have excellent
activity in biochemical induction assays at concentrations lower than
1 pg/ml, showing to be highly potent against Gram‐negative and ‐
positive bacteria. More interestingly, calicheamicin was demon-
strated to have extraordinary potency against tumor cells, showing
a roughly 4,000 and 1,000–10,000 times more potency than
adriamycin and clinically‐used anticancer drugs, respectively, with
an optimal dose at 0.5–1.5 μg/kg (Anderl et al., 2013; Dosio et al.,
2011; Edo et al., 1988; Golik et al., 1987a, 1987b; Lee et al., 1987a,
1987b, 1989; McDonald et al., 1996; Oku, Matsunaga, & Fusetani,
2003; Smith & Nicolaou, 1996).
Once inside the cells, calicheamicins, functionally similar to
anthracyclines, diffuse into the cell nucleus, target and bind to the
DNA minor groove, and site‐specifically induce double‐strand DNA
breaks, resulting in the cell death through apoptosis; in fact, reactive
diradical species, formed by calicheamicins, eventually result in DNA
strand cleavage at different locations, leading to rapid cell death via
apoptosis (Boger & Johnson, 1995; Gebleux & Casi, 2016; Jenkins,
Hurley, Neidle, & Thurston, 1994; Shor, Gerber, & Sapra, 2015;
Walker, Landovitz, Ding, Ellestad, & Kahne, 1992). In addition,
calicheamicins were demonstrated to result in altered expression of
various central cell elements at transcriptional levels, including
ribosomal and nuclear proteins, stress response‐related proteins,
various genes playing a role in DNA repair/synthesis, as well as
biosynthetic and metabolic genes (Dan et al., 2018; Watanabe,
Supekova, & Schultz, 2002). Most importantly, the drug less depends
upon cell‐cycle progression, making calicheamicin effectively appro-
priate against CSCs (Gupta, Chaffer, & Weinberg, 2009; Sapra,
Hooper, O'Donnell, & Gerber, 2011).
Among a variety of calicheamicin analogs identified in M.







Br (bromine‐containing analogs), Calicheamicin γ1I
(hereafter called calicheamicin) is the most intensively studied
calicheamicin, exhibiting highly potent cytotoxic effects (in vivo
potency: 0.15 μg/kg) (Dosio et al., 2011). Calicheamicin consists of
two structurally‐different areas, each containing a particular role in
the biological activity of the drug. The bigger part of the two areas
contains one extended sugar residue, consisting of a hexasubstituted
benzene ring and four monosaccharide units linked together via
glycosidic thioester and hydroxylamine linkages. The second struc-
tural region, the aglycon (also known as calicheamicinone), has a
condensed, highly‐functionalized bicyclic core harboring a strained
enediyne unit within a bridging 10‐member ring. The aryltetrasac-
charide is thought to deliver the drug to its target and strongly bind it
to the minor groove of double‐helix DNA (Dosio et al., 2011;
Nicolaou, Smith, & Yue, 1993).
Nevertheless, in spite of promising initial experiments showing a
potent activity at sub‐pM concentrations in vitro, their further
evaluation in preclinical models revealed that calicheamicins also
destroy the DNA of normal cells, have a low therapeutic index, and
cannot be used as a single therapeutic agent for cancer treatment.
This, thus, precluded further development for their application in
clinical settings. Nonetheless, the highly cytotoxic activity, the small
molecular size, and the defined mechanism of action turned
calicheamicins into an attractive payload for ADC synthesis (Anderl
et al., 2013). To this end, the natural trisulfide found in the
calicheamicin structure was converted to a disulfide, thus incorpor-
ating a functional group allowing its linkage to mAbs. In addition, a
hydrazide functionality has been introduced into calicheamicins to
conjugate them to mAbs through acid‐labile bonds (Frei, Elias,
Wheeler, Richardson, & Hryniuk, 1998). N‐acetyl‐calicheamicin γ1I
was selected as an ADC payload due to its appropriate stability as
compared with the calicheamicin γ1
I (Zein, Poncin, Nilakantan, &
Ellestad, 1989). Calicheamicin is currently being studied as a payload
in a variety of ADCs, importantly including FDA‐approved ADCs
gemtuzumab ozogamicin and inotuzumab ozogamicin. However, it is
important to note that calicheamicin has an extremely hydrophobic
nature, and only a few molecules can be conjugated to an antibody.
5.2.5 | Camptothecin analogs
Camptothecin (CPT) is a natural inhibitor of the nuclear enzyme
topoisomerase I with the potent anticancer activity initially isolated
in the 1980s from Camptothecaacuminata, the Chinese ornamental
tree. CPT molecules were demonstrated to have strong cytotoxic
activity against a broad range of experimental tumors and pre-
liminary clinical trials, inhibiting both DNA and RNA synthesis in
mammalian cells. Such naturally occurring products exert their
cytotoxic activity via binding to the topoisomerase I and DNA
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complex, preventing DNA religation and, therefore, resulting in DNA
damage and subsequent cell death through apoptosis (Pommier,
2006). Nevertheless, the drug activity is limited at physiological pH
because the lability of the CPT E ring lactone induces the formation
of the inactive hydroxy acid at this pH range. Of note, at acidic pH,
the reaction is reversible, providing a potential opportunity for
selectively targeting a variety of solid tumors that are surrounded by
acidic extracellular environment while maintaining normal intracel-
lular pH (Dancey & Eisenhauer, 1996; Hsiang, Hertzberg, Hecht, &
Liu, 1985).
Although CPTs show broad‐spectrum antitumor activity, their
low solubility and adverse effects are considered to be an important
pitfall. To circumvent these limitations, tremendous efforts have
been made toward the production of clinical CPT analogs. So far, the
FDA has approved two water‐soluble analogs: topotecan (TPT) and
irinotecan (camptothecin‐11, CPT‐11), demonstrating significant
antitumor activities in the clinic (Adams et al., 2000; Burke et al.,
2009). TPT and CPT‐11 have the same mechanism of action through
the topoisomerase I inhibitory activity and are thought to make use
of their toxic effects in the S‐phase of DNA synthesis, interfering with
cancer cell growth followed by cell death. TPT, a semi‐synthetic
derivative of CPT, which is primarily used to treat non‐small‐cell lung
cancer and advanced ovarian cancer, has been recently approved for
the treatment of cervical cancer. CPT‐11, a semi‐synthetic analog of
CPT approved by the FDA in 1996 which is used initially for the
treatment of colorectal cancer, is a prodrug converted into a more
potent CPT analog, SN‐38, under carboxylesterase action (Garcia‐
Carbonero & Supko, 2002; Satoh et al., 1994).
TPT, unlike CPT‐11, is not a prodrug and exists mostly in the
inactive carboxylate type at neutral pH. Clinical investigations using
CPT indicated that optimal efficacy of CPT‐11, TPT, and other CPT
analogs is obtained after continuous and extended exposure to low
concentrations of CPT (Gerrits, de Jonge, Schellens, Stoter, &
Verweij, 1997). This proposed that CPT or its CPT analogs can be
preferably suitable for ADC approaches, because of the fact that
antibodies show prolonged circulation half‐lives, often several days
to weeks (Burke et al., 2009; Carter & Senter, 2008; Wu & Senter,
2005). In addition, and importantly, topoisomerase I seems to be a
promising target for ADC development due to its role in cellular DNA
replication and transcription.
SN‐38 and DX‐8951f (DX‐8951; also known as exatecan
mesylate) are two analogs of CPT used as ADC payloads. SN‐38,
the active metabolite of CPT‐11, exerts its anticancer effects through
inhibition of DNA topoisomerase I (Starodub et al., 2015). SN‐38 has
nearly 1,000‐fold potency than CPT‐11, as a result of which the drug
cannot be administrated directly to patients due to high toxicity and
poor solubility (Starodub et al., 2015). The higher potency of SN‐38
makes the drug suitable for ADC synthesis. DX‐8951f is a CPT analog
with favorable characteristics as compared with TPT and CPT‐11,
including water solubility, stronger DNA topoisomerase I inhibitory,
lack of esterase‐dependent activation, and broad antitumor activity.
Importantly, DX‐8951f not only has greater antitumor activities as
compared with the other CPT analogs as well as SN‐38 (Nakada et al.,
2016), but also is not an MDR1 substrate, demonstrating to be
effective against MDR1 cancer cells (Beck et al., 2017; Ogitani et al.,
2016; Takegawa et al., 2017). DX‐8951f prevents topoisomerase I
activity through stabilizing a cleavable complex between DNA and
topoisomerase I and preventing religation of DNA breaks, therefore
leading to inhibition of DNA replication and induction of cell death.
This drug requires no enzymatic activation and displays greater
cytotoxic activity as compared with CPT and other CPT analogs.
5.2.6 | Other DNA‐damaging agents
Besides the abovementioned payloads, other molecules, which can be
used as a DNA‐damaging agent in ADC synthesis, include SGD‐1882
(a cytotoxic DNA minor groove cross‐linking derivative of PBD
dimers which is not an MDR1 substrate) (Kim & Kim, 2015),
centanamycin (an indolecarboxamide synthesized as a less toxic
analog of CC‐1065 and duocarmycin which binds to DNA and
alkylates or intercalates into the DNA) (Beck et al., 2011; Kim & Kim,
2015), PNU‐159682 (a highly potent metabolite of the anthracy-
clines which shows three folds more cytotoxicity compared with
doxorubicin) (Yu et al., 2015), and uncialamycin (an enediyne natural
product isolated from the Streptomyces uncialis) (Chowdari et al.,
2018), all showing acceptable potency against a broad range of
cancer cell lines. Indolinobenzodiazepine dimers, also known as IGNs,
are an indolino‐benzodiazepine dimer consisting of a mono‐imine
moiety, representing a novel set of cytotoxic agents with highly
potent activity in vitro (an IC50 value of low pM) against a variety of
cancer cells. IGNs, like the PBD dimer SJG‐136, are derived from the
natural anthramycin family. IGNs bind to the DNA minor groove and
their two imine functionalities are covalently reacted with guanine
residues, leading to DNA cross‐linking. It was demonstrated that the
substitution of the PBD pyrrolo group with an indolino moiety leads
to approximately 10‐fold more potent activity in vitro than SJG‐136,
presumably because of a faster rate of adduct formation with DNA.
5.3 | Alternative payloads
Most payloads used in ADC architectures, as mentioned above, have
been designed to directly disrupt important cellular machineries,
including DNA replication, DNA transcription, or tubulin polymeriza-
tion. All the abovementioned compounds, both microtubule‐targeting
payloads and DNA‐damaging payloads, have the following character-
istics: (a) a significantly higher cytotoxic potency (with an IC50 value
ranging from 0.01 to 0.1 nM) as compared with traditional
chemotherapeutic agents, such as doxorubicin that kills cells in the
100–1,000 nM concentration range, representing 100–1,000‐fold
more potent than payloads used in the first‐generation ADCs; (b)
cancer cell death through induction of apoptosis regardless of the
cell‐killing mechanism; (c) an appropriate functional group for
conjugation to an antibody (in the absence of a functional group,
the desired substituent can be introduced at an appropriate site to
maintain parent drug potency); (d) rational solubility in aqueous
solutions to enable the reaction with antibodies; and (e) extended
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stability in aqueous formulations commonly used for antibodies
(Abdollahpour‐Alitappeh et al., 2019; Chari, 2008; Dosio et al., 2011;
Smets, 1994).
However, in addition to the payloads discussed above, a variety
of recent investigations have assessed different pathways, and
opened interesting avenues into studying new mechanisms for
cytotoxicity, including direct induction of apoptosis, inhibition of
spliceosome, and inhibition of RNA polymerase.
5.3.1 | Bcl‐xL inhibitors
Cancer is generally nonresponsive to apoptosis‐associated signaling.
One of the mechanisms by which cancer cells acquire resistance to
apoptosis is the overexpression of antiapoptotic Bcl‐2 family
members, including Bcl‐xL. Agents capable of blocking the BH3‐
binding domain present on Bcl‐xL were demonstrated to prevent
unsuitable apoptotic functions and, most likely, trigger apoptosis in
cancer cells. In this regard, tremendous studies have been devoted to
investigate the possibility of ADC‐mediated delivery of Bcl‐xL
inhibitors. There are two anti‐EGFR Bcl‐xL ADCs that were
demonstrated to have acceptable activity in xenograft studies,
representing to be synergistic with docetaxel (Hennessy, 2016).
5.3.2 | Spliceosome inhibitors
RNA splicing is a key mechanism involved in translation of eukaryotic
genes. New pre‐mRNAs (messenger RNAs) are processed in the
spliceosome, a large ribonucleoprotein complex involved in mRNA
processing in eukaryotic cells. Misregulation or mutations in the
mRNA splicing machinery have been reported in several cancers.
Targeting the spliceosome using small molecules offers a promising
therapeutic option for targeted cancer therapy (Bonnal, Vigevani, &
Valcarcel, 2012; Butler, 2013; Kaida, Schneider‐Poetsch, & Yoshida,
2012). There are several natural products capable of inhibiting RNA
splicing through binding to different spliceosome subunits. Thailan-
statin A can bind to the SF3b subunit of the sliceosome, thus
preventing RNA splicing. In a study, an anti‐Her2 thailanstatin ADC
was demonstrated to exhibit the low nM activity in various
Her2‐expressing cell lines. Spliceostatins, a potent spliceosome
inhibitor, are bacterial natural products which exhibit promising
anticancer activity against a variety of cancer cell lines. The
mechanism of action as well as powerful cytotoxicity of such agents
have resulted in efforts to develop spliceosome inhibitors as
appropriate antitumor drugs (Eustaquio, Janso, Ratnayake,
O'Donnell, & Koehn, 2014).
5.3.3 | RNA polymerase inhibitors
The application of transcription inhibitors has paved a new strategic
avenue in the ADC field. RNA polymerase II is a critical enzyme
involved in DNA transcription into precursors of messenger RNA.
RNA polymerase inhibitors are effective cytotoxins capable of
directly blocking DNA transcription into mRNA. Amatoxins, a set of
macrocyclic peptides generated by mushrooms mainly by the genus
Amanita, are the most well‐known class of powerful and selective
inhibitors of RNA polymerase II, which inhibit protein synthesis
(Hallen, Luo, Scott‐Craig, & Walton, 2007; Lindell, Weinberg, Morris,
Roeder, & Rutter, 1970). Approximately nine naturally occurring
amatoxins have been identified so far, two of which, α‐amanitin and
β‐amanitin, account for approximately 90% of all amatoxins. In a
study, β‐amanitin was conjugated to a MUC1‐targeting mAb, which
showed specific cytotoxicity against T47D cells (Danielczyk et al.,
2006). α‐amanitin, a very water‐soluble mushroom‐derived octapep-
tide, is currently under investigation as an ADC payload in preclinical
studies (Lindell et al., 1970). In a study, α‐amanitin was effectively
delivered to the cancer cells via an HER2‐targeting mAb, showing
IC50 values in a pM range (Dan et al., 2018). In a recently developed
ADC, chiHEA125‐Ama, α‐amanitin has been conjugated to an
EpCAM‐targeting mAb, demonstrating potent in vitro and in vivo
antiproliferative activities (Moldenhauer et al., 2012). More recently,
an improvement has been observed in the in vivo antitumor
efficiency of anti‐PSMA‐α‐amanitin, when coupled through a stable
and cleavable linker (Dan et al., 2018). Taken together, the main
advantage for amatoxins, as a payload in ADCs, is their hydrophilic
character than other cytotoxic payloads, yielding the following
values: (a) the increased solubility and uniformity in aqueous
conditions, facilitating the conjugation reaction; (b) a decrease in
ADC aggregation, a phenomenon commonly seen with
hydrophobic payloads; (c) low molecular weight of the released drug
from disintegrated tumor cells, leading to low accumulation of the
drug in other tissues but quick excretion in urine; and (d), most
importantly, highly active in MDR cancer cells because of poor
substrates for MDR processes (Anderl et al., 2013; Kim & Kim, 2015).
6 | PAYLOADS IN THE MARKET AND
CLINICAL PIPELINES
ADC development has gained worldwide attention following the
recent approval of two ADCs (Besponsa and re‐approval of
Mylotarg). In fact, we are in an age of “ADC boom” with a large
number of novel and emerging ADCs under development or in
clinical trials. Of important note, the increasing number of ADCs in
the clinics, clinical trials, and research settings not only reflects the
growing interest and confidence of physicians and pharmaceutical
companies in the area, but also highlights the value and benefits that
ADCs provide to cancer patients.
However, despite the considerable growth in ADC pipelines over
the last 10 years, a significant portion of ADCs (approximately 30%)
has been discontinued for various reasons, a limited number of ADCs
have reach successful late stage trials, and only four ADCs have
received FDA approval, all for oncological indications. The four FDA‐
approved ADCs currently used to treat cancer patients include
gemtuzumab ozogamicin (Mylotarg), brentuximab vedotin (Adcetris),
trastuzumab emtansine (Kadcyla), and inotuzumab ozogamicin
(Besponsa) with calicheamicin, MMAE, DM1, and calicheamicin as
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payloads, respectively (Table 2) (Abdollahpour‐Alitappeh et al.,
2019). All of the abovementioned FDA‐approved ADCs were
demonstrated to be effective in patients with cancer. Although
withdrawn from the market because of concerns about safety and
clinical outcomes, gemtuzumab ozogamicin, an anti‐CD33‐calichea-
micin ADC, has been recently reintroduced into the US market in
2017. The re‐approval of gemtuzumab ozogamicin has demonstrated
that ADCs offer a clinically‐validated opportunity for the treatment
of patients with cancer.
Tables 3 and 4 summarize the ADCs in clinical trials, by focusing
on their payloads, sponsors, therapeutic indications, and status. The
data were retrieved from the clinical trials (https://clinicaltrials.gov).
The number of ADCs in clinical trials is quickly growing, so that more
than 100 different ADCs are currently in different phases of clinical
trials (approximately more than 250) for the treatment of various
cancers with more than 90 active ADCs (recruiting) under evaluation.
As shown in Tables 3,4, major pharmaceutical companies worldwide
contribute to the current flourishing number of ADCs in clinical
studies, which raises a new hope in the battle against different types
of cancers.
The majority of ADCs currently in clinical trials, although differing
in the mAb moiety targeting various cancers, only employ a small
number and common cytotoxic payloads, a great number of which
target microtubules or DNA and have high anticancer activity (with
an IC50 value of around 0.1 to 0.001 nM). More than 70% of the
ADCs in clinical trials utilize microtubule‐targeting payloads and only
29 ADCs utilize DNA‐disrupting agents in their structure. The
majority of the ADC payloads currently in clinical trials make use of
auristatins (MMAE and MMAF) and maytansinoids (DM1 and DM4)
as a payload. The recent approval of brentuximab vedotin and
trastuzumab emtansine shows that their payloads, an auristatin and a
maytansinoid, respectively, fulfill the criteria required for an
appropriate payload. The remaining payloads are based upon
tubulysins, PBDs, duocarmycins, doxorubicins, calicheamicins, IGNs,
and CPT‐11 derivatives. Calicheamicin, as a DNA‐disrupting
agent, was the first payload used in gemtuzumab ozogamicin, the
first‐commercially available ADC.
Auristatins are potent microtubule‐targeting agents which
constitute a majority of cytotoxic currently investigated payloads
used in ADCs. As mentioned above, MMAE and MMAF constitute the
largest class of ADCs in clinical trials, followed by maytansinoids
(DM1 and DM4) as the second largest one in clinical trials, which
have been used successfully in the ADC development.
A great number of PBDs and PBD dimers have been developed
for use in ADCs, some of which have been conjugated to different
mAbs. Since 2013, more than 10 ADCs consisting of PBD dimmers as
payloads have successfully entered clinical trials, making PBD
molecules the third most important payloads after auristatins and
maytansinoids. Though PBD molecules do not significantly interrupt
the DNA structure, vital DNA functions, such as transcription and
translation, are prevented through the formation of DNA‐PBD
adduct (Dan et al., 2018). There are two and three doxorubicin‐
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ADCs utilizing calicheamicin as their payload are currently being
evaluated in clinical studies, two of which have been approved by the
FDA. Developments described in the clinical trials hold great promise
for designing more diverse ADCs with significantly more successful
clinical pipelines.
7 | CONCLUSIONS AND FUTURE
DIRECTIONS
ADCs, as an attractive strategy to circumvent the limitations of a
single‐agent therapy, lead to preferential delivery of cytotoxic agents
into targeted cancer cells, thereby decreasing cellular cytotoxicity to
healthy tissues. Early ADCs used a variety of anticancer drugs, due to
their ready accessibility and well‐known toxicological characteristics;
however, it soon turned out that ADCs with such chemotherapeutic
agents, as a drug moiety, lack sufficient antitumor activity to be
useful for clinical application. Tremendous efforts over the past 10
years have then been focused on exploring the use of highly potent
molecules for ADC synthesis. This, in turn, leads to generation of
effective second‐ and third‐generation ADCs that take benefit of
highly potent payloads. Currently, most of the ADCs utilize two
families of highly toxic compounds as their payload moiety:
microtubule‐targeting agents and DNA‐damaging agents. Tubulin
inhibitors, such as auristatins and maytansines, are being widely used
as ADC payloads for ADC development. Such payloads selectively
target rapidly dividing cancer cells and are less susceptible to
nondividing normal cells. Alternatively, DNA‐damaging agents, such
as calicheamicins and PBDs, have the ability to cause apoptosis in all
cells, even in CSCs, but more likely have far more side effects.
However, despite advances in payload potency, the list of acceptable
payloads for application in ADC architecture has not increased. Indeed,
there are currently only a limited number of highly cytotoxic natural
compounds, derivatives, or synthetic analogs with the potential to be
used as a payload in the ADC architecture and to progress to the clinic.
The absence of payload diversity in the clinical studies might explain the
reason for dramatically high clinical failure rates.
Not surprisingly, in the next‐generation ADCs, it is projected that
the number of novel highly potent payloads with various mechanisms
of action, greater therapeutic efficacy, and fewer side effects rises in
the upcoming years for use in ADC architecture. Modern and
emerging medicinal chemistry can potentially help biological scien-
tists develop the next generation of ADC payloads with picomolar–-
femtomolar toxicity against a wide range of cancer cells. However,
challenges and difficulties involved in finding new drugs to be suited
as ADC payloads should be considered, including higher potency,
solubility, stability and hydrophilicity, as well as suitable activity
against drug‐resistant tumors and nontoxicity to normal cells/tissues.
Such new payloads with various mechanisms of action can
overcome resistance to currently used drugs. In addition, hybrid
payloads capable of targeting various binding sites on the tubulin
molecule or targeting both DNA and microtubule simultaneously may
circumvent ADC drug resistance. This is particularly important when
next‐generation ADCs are tailored to target solid tumors.
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